OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
INNO54

Innovassynth Technologies (India) Ltd

Specialty ChemicalsVerified

Innovassynth Technologies (India) Ltd exhibits a weak capital structure and liquidity position, with a current ratio of 0.01 and negative operating cash flow of -INR 7.26 million. The company’s debt-to-equity ratio is 0.1, indicating limited leverage, but its net income and operating income are both negative at -INR 46.87 million, reflecting poor profitability. Profitability metrics are significantly below industry norms, with a return on equity of -11.1% and return on assets of -9.65%. These figures suggest the company is underperforming relative to its peers in the specialty chemicals industry, where positive returns are typically expected. The company’s revenue is reported as zero, and no segment or geographic breakdown is available in the provided data. This lack of transparency limits the ability to assess revenue concentration or geographic exposure. Growth trajectory is negative, with no revenue reported and declining operating cash flow. The absence of revenue and the negative net income indicate a lack of operational momentum. No forward-looking guidance is provided in the outlook data. Risk factors include medium liquidity risk due to negative operating cash flow and a current ratio below 1. The risk assessment also flags negative net cash after subtracting total debt. Dilution risk is assessed as low, with no near-term pressure indicated. Recent filings and transcripts are not provided in the input data, so no specific events can be cited.

30-day price · INNO+2.02 (+3.1%)
Low$62.02High$82.66Close$67.36As of15 May, 00:00 UTC
Profile
CompanyInnovassynth Technologies (India) Ltd
TickerINNO.BO
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustrySpecialty Chemicals
AI analysis

Business. Innovassynth Technologies (India) Ltd operates in the specialty chemicals industry, producing and selling chemical products for industrial applications.

Classification. The company is classified under the Basic Materials economic sector, Chemicals business sector, and Specialty Chemicals industry with 92% confidence based on verified market data.

Innovassynth Technologies (India) Ltd exhibits a weak capital structure and liquidity position, with a current ratio of 0.01 and negative operating cash flow of -INR 7.26 million. The company’s debt-to-equity ratio is 0.1, indicating limited leverage, but its net income and operating income are both negative at -INR 46.87 million, reflecting poor profitability. Profitability metrics are significantly below industry norms, with a return on equity of -11.1% and return on assets of -9.65%. These figures suggest the company is underperforming relative to its peers in the specialty chemicals industry, where positive returns are typically expected. The company’s revenue is reported as zero, and no segment or geographic breakdown is available in the provided data. This lack of transparency limits the ability to assess revenue concentration or geographic exposure. Growth trajectory is negative, with no revenue reported and declining operating cash flow. The absence of revenue and the negative net income indicate a lack of operational momentum. No forward-looking guidance is provided in the outlook data. Risk factors include medium liquidity risk due to negative operating cash flow and a current ratio below 1. The risk assessment also flags negative net cash after subtracting total debt. Dilution risk is assessed as low, with no near-term pressure indicated. Recent filings and transcripts are not provided in the input data, so no specific events can be cited.
Key takeaways
  • The company has a weak capital structure and liquidity position, with a current ratio of 0.01.
  • Profitability is negative, with return on equity and return on assets both below zero.
  • No revenue is reported, and the company is experiencing declining operating cash flow.
  • Liquidity risk is medium, and the company has negative net cash after subtracting total debt.
  • --
  • ## RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$0.00
Gross profit-$4.0M
Operating income-$46.9M
Net income-$46.9M
R&D
SG&A
D&A
SBC
Operating cash flow-$7.3M
CapEx
Free cash flow
Total assets$486.0M
Total liabilities$63.5M
Total equity$422.4M
Cash & equivalents$530.0k
Long-term debt$44.0M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$422.4M
Net cash-$43.4M
Current ratio0.0
Debt/Equity0.1
ROA-9.7%
ROE-11.1%
Cash conversion15.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
MetricINNOActivity
Op margin0.4% medp25 -8.0% · p75 16.0%
Net margin2.3% medp25 -11.6% · p75 11.8%
Gross margin20.8% medp25 14.9% · p75 24.0%
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue6.2% medp25 5.4% · p75 10.2%
Debt / equity10.0%59.0% medp25 54.9% · p75 72.9%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 05:08 UTC#39fb6e85
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 05:09 UTCJob: 279cdebd